Overview

Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-20
Target enrollment:
Participant gender:
Summary
To evaluate the additional efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced liver cancer and treated with tyrosine kinase inhibitors (TKIs) combined with immunotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
Xu Yong, MD
Collaborator:
Nanjing Xiershou Biotechnology Co., Ltd
Treatments:
lenvatinib